RBC Capital Maintains Outperform on Moderna, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Moderna (NASDAQ:MRNA) and raises the price target from $135 to $160.
June 03, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Moderna and raises the price target from $135 to $160.
The raised price target and maintained Outperform rating from RBC Capital are positive signals for investors, likely leading to a short-term increase in Moderna's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100